SCHEMBL2947410

SCHEMBL2947410

COCCOc1ccc2oc(C(=O)Nc3ccc(Cl)cn3)c(NC(=O)C3CCC(N(C)C(C)=O)CC3)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.44
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ MAPT P10636 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ TP53 P04637 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ DHODH Q02127 1/20 0.41
▸ F10 P00742 6/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ CASP3 P42574 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2947411 1.00 HSD17B10 (0.44) HSD17B10MEN1KMT2AMAPTTSHR
SCHEMBL13744760 0.88 HSD17B10 (0.44) HSD17B10MEN1KMT2AMAPTTSHR
SCHEMBL2949750 0.87 SMN1; SMN2 (0.43) HSD17B10MEN1KMT2AMAPTTSHR
Hydrochloric Acid SCHEMBL2947407 0.87 HSD17B10 (0.44) HSD17B10MEN1KMT2AMAPTTSHR
SCHEMBL2949754 0.87 SMN1; SMN2 (0.43) HSD17B10MEN1KMT2AMAPTTSHR
Hydrochloric Acid SCHEMBL2947408 0.87 HSD17B10 (0.44) HSD17B10MEN1KMT2AMAPTTSHR
SCHEMBL2945033 0.87 SMN1; SMN2 (0.41) HSD17B10MEN1KMT2AMAPTTSHR
SCHEMBL2945036 0.87 SMN1; SMN2 (0.41) HSD17B10MEN1KMT2AMAPTTSHR
SCHEMBL2949505 0.86 SMN1; SMN2 (0.44) HSD17B10MEN1KMT2AMAPTTSHR
SCHEMBL2949504 0.86 SMN1; SMN2 (0.44) HSD17B10MEN1KMT2AMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1489078-B1 BENZOFURAN DERIVATIVE MITSUBISHI TANABE PHARMA CORP (JP) 2010-01-06 — — EP disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-7531537-B2 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-12 — — US disclosed
US-20050282808-A1 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282808-A1 Benzofuran derivative F12, F2, F11 HSD17B10 904/4885MEN1 2756/4885KMT2A 1500/4885
US-20090209511-A1 Benzofuran Derivatives F12, F2, F3 HSD17B10 922/4885MEN1 2864/4885KMT2A 1518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback